AR111367A1 - N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso - Google Patents
N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su usoInfo
- Publication number
- AR111367A1 AR111367A1 ARP180100886A ARP180100886A AR111367A1 AR 111367 A1 AR111367 A1 AR 111367A1 AR P180100886 A ARP180100886 A AR P180100886A AR P180100886 A ARP180100886 A AR P180100886A AR 111367 A1 AR111367 A1 AR 111367A1
- Authority
- AR
- Argentina
- Prior art keywords
- fluorine
- substituted
- alkyl
- trisubstituted
- phenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Compuestos de la fórmula (1), caracterizados porque Ar representa fenilo o piridilo, donde fenilo puede estar hasta tetrasustituido y piridilo hasta disustituido, en cada caso de manera igual o diferente, con flúor, cloro, con alquilo C₁₋₄ hasta trisustituido con flúor, con cicloalquilo C₃₋₄ hasta tetrasustituido con flúor, con alcoxi C₁₋₂ hasta trisustituido con flúor, o con alquilsulfanilo C₁₋₂ hasta trisustituido con flúor, o donde dos sustituyentes del grupo fenilo o piridilo, si están unidos a átomos anulares adyacentes, dado el caso están unidos de manera tal que juntos forman un grupo metilendioxi- o etilendioxi, o donde fenilo puede estar sustituido hasta cinco veces con flúor; Y representa una unión o un grupo de la fórmula: #¹-X-(CR¹⁰AR¹⁰B)ₖ-#², donde #¹ representa el punto de unión con el átomo de carbono; #² representa el punto de unión con el grupo carboxi; X representa una unión, -CH₂-, -O-, -S(=O)ₘ- o -N(R¹¹)-, en la que m significa 0, 1 ó 2, y R¹¹ significa hidrógeno o metilo; R¹⁰A y R¹⁰B independientemente entre sí representan hidrógeno, flúor o metilo, o R¹⁰A y R¹⁰B forman junto con el átomo de carbono al que están unidos, un grupo ciclopropilo; k representa 1, 2, 3 ó 4; R¹ representa halógeno, alquilo C₁₋₄ sustituido hasta cinco veces con flúor, metoxi hasta trisustituido con flúor, (trifluorometil)sulfanilo, pentafluorosulfanilo, trimetilsililo, etinilo, ciclopropilo, o ciclobutilo, donde ciclopropilo y ciclobutilo pueden estar sustituidos hasta cuatro veces con flúor; R², R³ y R⁴ independientemente entre sí representan hidrógeno, halógeno o metilo hasta trisustituido con flúor; R⁵ representa halógeno, alquilo C₁₋₄ sustituido hasta cinco veces con flúor, metoxi hasta trisustituido con flúor, hidroxi, metilsulfanilo, (trifluorometil)sulfanilo, ciano, etenilo, ciclopropilo o ciclobutilo, donde ciclopropilo y ciclobutilo pueden estar sustituidos hasta cuatro veces con flúor; R⁶ representa -NR¹²R¹³, donde R¹² significa hidrógeno o alquilo C₁₋₃, y R¹³ significa alquilo C₁₋₄ o cicloalquilo C₃₋₇, donde cicloalquilo C₃₋₇ puede estar sustituido hasta cuatro veces con flúor y alquilo C₁₋₄ puede estar sustituido hasta cinco veces con flúor o estar monosustituido con cicloalquilo C₃₋₆, metoxi, trifluorometoxi o fenilo, donde fenilo puede estar hasta trisustituido con flúor, o representa un heterociclo bicíclico de 6 a 10 miembros, monocíclico de 4 a 8 miembros, saturado o parcialmente insaturado, unido por medio de un átomo de nitrógeno, que puede contener un heteroátomo adicional, igual o diferente de la serie N, O, S, SO o SO₂ como miembro anular, donde el heterociclo bicíclico de 6 a 10 miembros, monocíclico de 4 a 8 miembros puede estar sustituido en cada caso con 1 a 3 sustituyentes seleccionados independientemente entre sí del grupo alquilo C₁₋₄, hidroxi, oxo, alcoxi C₁₋₃, difluorometoxi, trifluorometoxi, ciano, amino, monometilamino, dimetilamino, aminocarbonilo, monometilaminocarbonilo, dimetilaminocarbonilo y además puede estar sustituido hasta cuatro veces con flúor, donde alquilo C₁₋₄ puede estar sustituido hasta cinco veces con flúor o estar monosustituido con hidroxi o metoxi; R⁷A y R⁷B independientemente entre sí representan hidrógeno o metilo, o R⁷A y R⁷B forman junto con el átomo de carbono al que están unidos, un grupo ciclopropilo; R⁸ representa hidrógeno, flúor, metilo, trifluorometilo, etilo o hidroxi; R⁹ representa hidrógeno o metilo; así como sus N-óxidos, sales, solvatos, sales de los N-óxidos y solvatos de los N-óxidos y sales.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17165674 | 2017-04-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR111367A1 true AR111367A1 (es) | 2019-07-03 |
Family
ID=58530431
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP180100886A AR111367A1 (es) | 2017-04-10 | 2018-04-10 | N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso |
Country Status (19)
Country | Link |
---|---|
US (1) | US11149018B2 (es) |
EP (1) | EP3609870A1 (es) |
JP (1) | JP7125420B2 (es) |
KR (1) | KR20190138825A (es) |
CN (1) | CN110709384A (es) |
AR (1) | AR111367A1 (es) |
AU (1) | AU2018251087B2 (es) |
BR (1) | BR112019021130A2 (es) |
CA (1) | CA3059954A1 (es) |
CO (1) | CO2019011227A2 (es) |
EA (1) | EA201992389A1 (es) |
IL (1) | IL269836B (es) |
MX (1) | MX2019012152A (es) |
PE (1) | PE20191738A1 (es) |
PH (1) | PH12019502315A1 (es) |
TW (1) | TWI770157B (es) |
UA (1) | UA125660C2 (es) |
UY (1) | UY37671A (es) |
WO (1) | WO2018189012A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2007009796A (es) | 2007-08-14 | 2009-02-25 | Cell Therapy And Technology S | Gel conteniendo pirfenidona. |
MX346763B (es) | 2012-03-28 | 2017-03-31 | Cell Therapy And Tech S A De C V | Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné. |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2227769T3 (es) * | 1994-05-27 | 2005-04-01 | Glaxosmithkline S.P.A. | Derivados de quinolina como antagonistas del receptor nk3 de taquiquinina. |
IT1270615B (it) * | 1994-07-14 | 1997-05-07 | Smithkline Beecham Farma | Uso di derivati di chinolina |
AR004735A1 (es) * | 1995-11-24 | 1999-03-10 | Smithkline Beecham Spa | Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento. |
DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
GB9825554D0 (en) | 1998-11-20 | 1999-01-13 | Smithkline Beecham Spa | Novel Compounds |
WO2000064877A1 (en) | 1999-04-26 | 2000-11-02 | Neurogen Corporation | 2-aminoquinolinecarboxamides: neurokinin receptor ligands |
DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
EP1856099A2 (en) | 2005-03-03 | 2007-11-21 | Sirtris Pharmaceuticals, Inc. | Acridine and quinoline derivatives as sirtuin modulators |
KR101762574B1 (ko) | 2009-03-31 | 2017-07-28 | 가부시키가이샤 레나사이언스 | 플라즈미노겐 액티베이터 인히비터-1 저해제 |
GB2470833B (en) * | 2009-06-03 | 2011-06-01 | Amira Pharmaceuticals Inc | Polycyclic antagonists of lysophosphatidic acid receptors |
DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
EA201390060A1 (ru) | 2010-07-09 | 2013-07-30 | Байер Интеллектуэль Проперти Гмбх | Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний |
DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
US20140275224A1 (en) | 2010-11-05 | 2014-09-18 | Regents Of The University Of Minnesota | Cytosine deaminase modulators for enhancement of dna transfection |
US9051305B2 (en) | 2011-03-08 | 2015-06-09 | Eutropics Pharmaceuticals, Inc. | Compositions and methods useful for treating diseases |
US9309187B2 (en) | 2012-05-03 | 2016-04-12 | Takeda Gmbh | EP2 receptor agonists |
TWI572597B (zh) * | 2012-06-29 | 2017-03-01 | 美國禮來大藥廠 | 二甲基-苯甲酸化合物 |
CA2898615A1 (en) | 2013-01-28 | 2014-07-31 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitor compounds |
CA2929562A1 (en) | 2013-12-17 | 2015-06-25 | Eli Lilly And Company | Dimethylbenzoic acid compounds |
WO2016004035A1 (en) | 2014-07-01 | 2016-01-07 | Icahn School Of Medicine At Mount Sinai | 2-aryl-4-quinolinecarboxamide derivatives for treating thyroid diseases |
WO2016037954A1 (de) * | 2014-09-09 | 2016-03-17 | Bayer Pharma Aktiengesellschaft | Substituierte n,2-diarylchinolin-4-carboxamide und ihre anti-inflammatorische verwendung |
CA2964113A1 (en) | 2014-10-14 | 2016-04-21 | La Jolla Institute Of Allergy & Immunology | Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof |
JP2018512404A (ja) * | 2015-03-18 | 2018-05-17 | バイエル ファーマ アクチエンゲゼルシャフト | 置換n−ビシクロ−2−アリール−キノリン−4−カルボキサミドおよびその使用 |
UY36629A (es) | 2015-04-17 | 2016-11-30 | Abbvie Inc | Indazolonas como moduladores de la señalización de tnf |
-
2018
- 2018-04-03 TW TW107111781A patent/TWI770157B/zh not_active IP Right Cessation
- 2018-04-04 US US16/604,157 patent/US11149018B2/en active Active
- 2018-04-04 CN CN201880038373.4A patent/CN110709384A/zh active Pending
- 2018-04-04 KR KR1020197032878A patent/KR20190138825A/ko not_active Application Discontinuation
- 2018-04-04 BR BR112019021130-6A patent/BR112019021130A2/pt not_active IP Right Cessation
- 2018-04-04 AU AU2018251087A patent/AU2018251087B2/en not_active Ceased
- 2018-04-04 EA EA201992389A patent/EA201992389A1/ru unknown
- 2018-04-04 PE PE2019002011A patent/PE20191738A1/es unknown
- 2018-04-04 MX MX2019012152A patent/MX2019012152A/es unknown
- 2018-04-04 UA UAA201911039A patent/UA125660C2/uk unknown
- 2018-04-04 JP JP2019555205A patent/JP7125420B2/ja active Active
- 2018-04-04 EP EP18713990.2A patent/EP3609870A1/de not_active Withdrawn
- 2018-04-04 WO PCT/EP2018/058613 patent/WO2018189012A1/de unknown
- 2018-04-04 CA CA3059954A patent/CA3059954A1/en active Pending
- 2018-04-10 UY UY0001037671A patent/UY37671A/es not_active Application Discontinuation
- 2018-04-10 AR ARP180100886A patent/AR111367A1/es unknown
-
2019
- 2019-10-06 IL IL269836A patent/IL269836B/en unknown
- 2019-10-09 CO CONC2019/0011227A patent/CO2019011227A2/es unknown
- 2019-10-09 PH PH12019502315A patent/PH12019502315A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR112019021130A2 (pt) | 2020-09-01 |
CA3059954A1 (en) | 2018-10-18 |
EP3609870A1 (de) | 2020-02-19 |
PH12019502315A1 (en) | 2020-07-06 |
CN110709384A (zh) | 2020-01-17 |
EA201992389A1 (ru) | 2020-04-03 |
TW201900616A (zh) | 2019-01-01 |
AU2018251087B2 (en) | 2021-11-18 |
JP7125420B2 (ja) | 2022-08-24 |
US20200157073A1 (en) | 2020-05-21 |
JP2020513026A (ja) | 2020-04-30 |
CO2019011227A2 (es) | 2019-10-21 |
KR20190138825A (ko) | 2019-12-16 |
WO2018189012A1 (de) | 2018-10-18 |
IL269836B (en) | 2022-04-01 |
UY37671A (es) | 2018-11-30 |
PE20191738A1 (es) | 2019-12-12 |
TWI770157B (zh) | 2022-07-11 |
UA125660C2 (uk) | 2022-05-11 |
AU2018251087A1 (en) | 2019-10-31 |
US11149018B2 (en) | 2021-10-19 |
MX2019012152A (es) | 2019-11-21 |
IL269836A (en) | 2019-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1120988T1 (el) | Παρεμποδιστες διαρυλ κινασης | |
AR109805A1 (es) | Derivados de oxadiazol microbiocidas | |
AR099023A1 (es) | Pirazolil-heteroarilamidas como agentes plaguicidas | |
CL2018003504A1 (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplasicos. | |
BR112017003898A2 (pt) | análogos de dioxolano de uridina para o tratamento de câncer | |
AR094557A1 (es) | Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con deficiencia de smn | |
AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
AR097866A1 (es) | Derivados de 4-azaindol | |
AR102258A1 (es) | Compuestos de quinolina y quinazolina | |
AR109706A1 (es) | INHIBIDORES DUALES DE FOSFATIDILINOSITOL 3 QUINASA d / g | |
CL2019000462A1 (es) | Compuestos derivados de indol, composiciones que los contienen, útiles en el tratamiento de infestación por helmintos, preferentemente trematodos, en mamíferos. (divisional solicitud 201603258) | |
AR100327A1 (es) | Inhibidores de quinasa relacionados con tropomiosina | |
AR114729A1 (es) | Análogos de hexahidropirimidina antimalaria | |
AR111367A1 (es) | N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso | |
AR095040A1 (es) | Antagonistas de h3 que contienen un núcleo estructural de fenoxipiperidina | |
AR100448A1 (es) | 5-(hetero)aril-piridazinonas y su uso como herbicida | |
AR096490A1 (es) | Moduladores del receptor cxcr7 | |
AR100706A1 (es) | Derivados de naftiridinadiona | |
AR107570A1 (es) | Compuestos químicos | |
AR096984A1 (es) | Derivados 1-(piperazin-1-il)-2-([1,2,4]triazol-1-il)-etanona | |
AR098713A1 (es) | 4-amino-6-(halo-alquil-sustituido)-picolinatos y su uso como herbicidas | |
AR113227A1 (es) | Compuestos y composiciones para inducir condrogénesis | |
AR092145A1 (es) | Tris-(hetero)aril-pirazoles y su uso | |
AR111474A1 (es) | Compuestos químicos | |
AR107426A1 (es) | DERIVADOS DE N-INDEN-AMIDA COMO MODULADORES DEL mGluR7 |